ĀÜĄņĀŅĀ×

Before joining T3D Therapeutics, Dr. Chamberlain served as Chief Scientific Officer for PurThread Technologies, Inc. He was responsible for chemistry and biology for PurThread from June of 2012 until November 2013. Prior to joining PurThread, Dr. Chamberlain served as Vice President of Chemistry at Inhibitex, Inc. from early 2008 to 2012 where he was responsible for the research and development of the anti-HCV compound INX-08189, working with academic and industrial collaborators. Prior to joining Inhibitex, he was Senior Group Manager in Medicinal Chemistry Oncology at Glaxo SmithKline in Research Triangle Park, NC from 2001 to 2007, working in the area of protein kinase inhibitors. From 1995 to 2001, Dr. Chamberlain was a Group Leader in Medicinal Chemistry at Glaxo Wellcome, working in the areas of antiviral and anti-inflammatory chemotherapy. From 1986 to 1995, he held several Senior Scientist positions in the Experimental Therapy Department at Burroughs Wellcome, focusing on nucleoside agents for anti-viral and oncology applications. Dr. Chamberlain received his Ph.D. in Synthetic Organic Chemistry from the University of Iowa. Dr. Chamberlainā€™s publications and patents cover the areas of anti-viral, anti-cancer, and anti-inflammation chemotherapy, with a focus on protein kinase inhibitors and nucleoside derivatives.